Taurine activates AMP-activated protein kinase (AMPK) through increased cellular energy stress signaling, enhancing mitochondrial biogenesis and oxidative capacity while suppressing mTOR-mediated anabolic pathways. This modulation addresses the hallmark aging process of impaired proteostasis and mitochondrial dysfunction by promoting autophagy, reducing reactive oxygen species production, and improving metabolic flexibility. Preclinical evidence demonstrates taurine supplementation extends lifespan in model organisms and improves age-related metabolic parameters, while recent human observational data associates higher circulating taurine with reduced all-cause mortality and lower cardiometabolic disease risk in aging populations. Current mechanistic understanding suggests taurine's benefits operate primarily through AMPK-dependent pathways that recapitulate caloric restriction and exercise-induced metabolic adaptations.
Taurine is an amino acid sold as a dietary supplement and is not FDA-approved as a drug for any indication, including longevity.
A notable mouse lifespan study (Singh 2023) has driven recent interest, with human trial data still emerging. Geroevidence's profile is currently marked under editorial review as evidence accumulates.
Geroevidence adds a formal evidence tier once a minimum threshold is met — at least one published human trial or strong ITP-style lifespan data. Taurine's human evidence base is still developing.
Taurine has a long history of use as a dietary supplement with a generally favorable safety profile at studied doses; longevity-specific human safety data is still accumulating.
The Singh 2023 mouse lifespan study positions taurine alongside other ITP-style lifespan-extension compounds tracked on Geroevidence, though its human evidence base remains earlier-stage. See the acarbose profile for an ITP comparison.